PMID- 34699323
OWN - NLM
STAT- MEDLINE
DCOM- 20220218
LR  - 20220218
IS  - 2165-5987 (Electronic)
IS  - 2165-5979 (Print)
IS  - 2165-5979 (Linking)
VI  - 12
IP  - 2
DP  - 2021 Dec
TI  - Astragalus polysaccharide improve the proliferation and insulin secretion of 
      mouse pancreatic beta cells induced by high glucose and palmitic acid partially 
      through promoting miR-136-5p and miR-149-5p expression.
PG  - 9872-9884
LID - 10.1080/21655979.2021.1996314 [doi]
AB  - The current drugs for the treatment of type 2 diabetes mellitus (T2DM) can cause 
      side effects after long-time use. Hence, the novel drugs were urgent need to 
      developed for T2DM patients. In this study, the effect of astragalus 
      polysaccharide on dysfunctional insulin cells was investigated to clarify whether 
      astragalus polysaccharide could be a novel drug for T2DM treatment. MIN6 cells 
      (mouse pancreatic beta-cell line) were treated with high glucose (HG)+ palmitic acid 
      (PA) and then treated with astragalus polysaccharide. The proliferation, 
      apoptosis, and insulin secretion were measured using CCK8, flow cytometry, and 
      ELISA, respectively. Pancreatic and duodenal homeobox 1 (PDX1), miR-136-5p, and 
      miR-149-5p expression levels were measured by RT-qPCR. The combination of EF-hand 
      domain family member 2 (EFHD2) and miR-136-5p or miR-149-5p was analyzed by 
      luciferase reporter assay. EFHD2 protein level was measured by western blot. We 
      found that HG+PA treatment reduced MIN6 cell viability, insulin secretion, and 
      PDX1 expression and promoted MIN6 cell apoptosis. Astragalus polysaccharide 
      treatment reversed the effect of HG+PA on MIN6 cells. Additionally, astragalus 
      polysaccharide treatment promoted miR-136-5p and miR-149-5p expression. Silencing 
      of miR-136-5p and miR-149-5p expression partially reversed the therapeutic 
      effects of astragalus polysaccharide. Furthermore, EFHD2 was the target of 
      miR-136-5p and miR-149-5p. Meanwhile, astragalus polysaccharide treatment 
      inhibited EFHD2 protein level in HG+PA treated MIN6 cell. Finally, EFHD2 
      overexpression partially reversed the therapeutic effects of astragalus 
      polysaccharide. In conclusion, astragalus polysaccharide treatment improved 
      proliferation and insulin secretion in HG+PA-treated MIN6 cells partially by 
      promoting miR-136-5p and miR-149-5p expression to inhibit EFHD2 expression.
FAU - Deng, Shifang
AU  - Deng S
AD  - Department of Traditional Chinese Medicine, Shenzhen People's Hospital (The 
      Second Clinical Medical College, Jinan University; The First Affiliated Hospital, 
      Southern University of Science and Technology), Shenzhen 518020, Guangdong, 
      China.
FAU - Yang, Lei
AU  - Yang L
AD  - Department of Geriatrics in Luohu Hospital of Traditional Chinese Medicine, 
      Shenzhen Hospital of Shanghai University of traditional Chinese Medicine, 
      Shenzhen, China.
FAU - Ma, Ke
AU  - Ma K
AD  - Department of Traditional Chinese Medicine, Shenzhen People's Hospital (The 
      Second Clinical Medical College, Jinan University; The First Affiliated Hospital, 
      Southern University of Science and Technology), Shenzhen 518020, Guangdong, 
      China.
FAU - Bian, Wei
AU  - Bian W
AD  - Department of Traditional Chinese Medicine, Shenzhen People's Hospital (The 
      Second Clinical Medical College, Jinan University; The First Affiliated Hospital, 
      Southern University of Science and Technology), Shenzhen 518020, Guangdong, 
      China.
LA  - eng
PT  - Journal Article
PT  - Video-Audio Media
PL  - United States
TA  - Bioengineered
JT  - Bioengineered
JID - 101581063
RN  - 0 (MIRN149 microRNA, mouse)
RN  - 0 (MicroRNAs)
RN  - 0 (Mirn136 microRNA, mouse)
RN  - 0 (Polysaccharides)
RN  - 2V16EO95H1 (Palmitic Acid)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - Astragalus Plant/*chemistry
MH  - Cell Line
MH  - Cell Proliferation/*drug effects
MH  - Gene Expression Regulation/*drug effects
MH  - Glucose/*pharmacology
MH  - Insulin Secretion/*drug effects
MH  - Insulin-Secreting Cells/*metabolism
MH  - MicroRNAs/*biosynthesis
MH  - Palmitic Acid/*pharmacology
MH  - Polysaccharides/chemistry/*pharmacology
PMC - PMC8810136
OTO - NOTNLM
OT  - Diabetes mellitus
OT  - Huang qi
OT  - Insulin-secreting Cells
OT  - MicroRNAs
OT  - Polysaccharides
COIS- No potential conflict of interest was reported by the author(s).
EDAT- 2021/10/27 06:00
MHDA- 2022/02/19 06:00
PMCR- 2021/12/07
CRDT- 2021/10/26 17:20
PHST- 2021/10/27 06:00 [pubmed]
PHST- 2022/02/19 06:00 [medline]
PHST- 2021/10/26 17:20 [entrez]
PHST- 2021/12/07 00:00 [pmc-release]
AID - 1996314 [pii]
AID - 10.1080/21655979.2021.1996314 [doi]
PST - ppublish
SO  - Bioengineered. 2021 Dec;12(2):9872-9884. doi: 10.1080/21655979.2021.1996314.